SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals gains on entering into exclusive agreement with SCD

22 Feb 2018 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 525.20, up by 0.50 points or 0.10% from its previous closing of Rs. 524.70 on the BSE.

The scrip opened at Rs. 527.95 and has touched a high and low of Rs. 527.95 and Rs. 525.00 respectively.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 957.50 on 22-Feb-2017 and a 52 week low of Rs. 517.40 on 19-Feb-2018.

Last one week high and low of the scrip stood at Rs. 532.05 and Rs. 517.40 respectively. The current market cap of the company is Rs. 14,819.00 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 37.07% and 16.40% respectively.

Glenmark Pharmaceuticals has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.

It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the US brand sales for the six products was approximately $1.7 billion for calendar year 2017.

Glenmark Pharmaceuticals (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries.

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×